MANWANI HARISH 4

What Happened

• Harish Manwani, a director of Gilead Sciences (GILD), was granted equity on April 30, 2026: 1,146 restricted stock units (RSUs) and 4,884 shares tied to a stock option award (reported as a derivative acquisition). Both awards vested immediately upon grant. To cover tax withholding, 224 shares were surrendered/withheld at $130.84 per share, generating $29,308 in value.
• These transactions are awards/grants (acquisitions) rather than open-market purchases or routine sales; the only disposal was the 224-share tax withholding.

Key Details

• Transaction date: April 30, 2026; Form 4 filed May 4, 2026 (period of report: 2026-04-30).
• Prices reported: Grants recorded at $0.00 (typical for RSU/award reporting); 224 shares withheld at $130.84 each = $29,308 total.
• Shares owned after the transactions: Not specified in the filing.
• Footnotes:
  • F1: 1,146 RSUs granted under the 2022 Equity Incentive Plan; each RSU converts to one share and these vested immediately on April 30, 2026.
  • F2: 100% of the shares subject to the reported stock option vested immediately on April 30, 2026.
• Disposal code F indicates the 224-share transfer was to cover tax liability, not an open-market sale.

Context

• The 4,884-share entry is a derivative award (stock option-related) that vested immediately; this is not the same as a market purchase. The 224 shares surrendered were used for tax withholding (a routine administrative step) and do not necessarily indicate a change in the director’s view of the company.
• Awards and withholding are common compensation events for insiders; purchases (buys) generally provide clearer signals of insider confidence, while grants and withholding are primarily compensation mechanics.